All of DSpace

Show simple item record

Anti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patient

dc.creatorEleftheriadis T., Pissas G., Liakopoulos V., Stefanidis I.en
dc.date.accessioned2023-01-31T07:37:17Z
dc.date.available2023-01-31T07:37:17Z
dc.date.issued2021
dc.identifier10.1097/CJI.0000000000000365
dc.identifier.issn15249557
dc.identifier.urihttp://hdl.handle.net/11615/71340
dc.description.abstractImmune checkpoint inhibitors by blocking specific inhibitory pathways induce T-cell-mediated tumor lysis. However, many remain to be elucidated about their effect on human humoral immunity. We evaluated the effect of the PD1 inhibitor nivolumab on humoral immunity by following the levels of antibodies against hepatitis B surface antigen (anti-HBs) in a hemodialysis patient successfully vaccinated against hepatitis B virus 5 years ago and now starting nivolumab for renal cell carcinoma lung metastases. Anti-HBs kinetics after administration of an extra vaccine dose were also evaluated. Nivolumab increased anti-HBs and facilitated a further increase following an additional vaccine dose. The observed time frame indicates that nivolumab boosts humoral immune response by affecting long-lived plasma cells and at least memory B cells. This may protect cancer patients from pathogens encountered in the past or against which vaccination has been performed and provide information for the emerging immune checkpoint inhibitors administration concept against chronic infectious diseases. © 2021 Lippincott Williams and Wilkins. All rights reserved.en
dc.language.isoenen
dc.sourceJournal of Immunotherapyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85103994430&doi=10.1097%2fCJI.0000000000000365&partnerID=40&md5=7f09743448de50c87a953d85f6ea380d
dc.subjecthepatitis B surface antigenen
dc.subjectnivolumaben
dc.subjectrecombinant hepatitis B vaccineen
dc.subjecthepatitis B antibodyen
dc.subjecthepatitis B surface antigenen
dc.subjecthepatitis B vaccineen
dc.subjectnivolumaben
dc.subjectPDCD1 protein, humanen
dc.subjectprogrammed death 1 receptoren
dc.subjectadulten
dc.subjectantigen blood levelen
dc.subjectArticleen
dc.subjectcancer immunotherapyen
dc.subjectcase reporten
dc.subjectclinical articleen
dc.subjectdisease predispositionen
dc.subjectdrug tolerabilityen
dc.subjectelectrochemiluminescenceen
dc.subjectfollow upen
dc.subjecthemodialysis patienten
dc.subjecthepatitis Ben
dc.subjecthumanen
dc.subjecthumoral immunityen
dc.subjectkidney hypoplasiaen
dc.subjectlung metastasisen
dc.subjectlung noduleen
dc.subjectmaleen
dc.subjectmemory cellen
dc.subjectmiddle ageden
dc.subjectnephrectomyen
dc.subjectplasma cellen
dc.subjectpriority journalen
dc.subjectrenal cell carcinomaen
dc.subjecttreatment responseen
dc.subjectvaccinationen
dc.subjecthemodialysisen
dc.subjecthepatitis Ben
dc.subjecthumoral immunityen
dc.subjectimmunologyen
dc.subjectimmunotherapyen
dc.subjectkidney tumoren
dc.subjectmetabolismen
dc.subjectproceduresen
dc.subjectHepatitis Ben
dc.subjectHepatitis B Antibodiesen
dc.subjectHepatitis B Surface Antigensen
dc.subjectHepatitis B Vaccinesen
dc.subjectHumansen
dc.subjectImmune Checkpoint Inhibitorsen
dc.subjectImmunity, Humoralen
dc.subjectImmunotherapyen
dc.subjectKidney Neoplasmsen
dc.subjectMaleen
dc.subjectMemory B Cellsen
dc.subjectMiddle Ageden
dc.subjectNivolumaben
dc.subjectProgrammed Cell Death 1 Receptoren
dc.subjectRenal Dialysisen
dc.subjectLippincott Williams and Wilkinsen
dc.titleAnti-PD1 Immunotherapy for Metastatic Renal Cancer Boosted Humoral Immunity in a Hemodialysis Patienten
dc.typejournalArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record